Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
ConclusionsThe decrease in rates of TEAEs and the stable rates of SAEs, other malignancies and MACE during up to 5 years of ixekizumab dosing are consistent with previous reports describing a favorable safety profile of ixekizumab following shorter durations of exposure.FundingEli Lilly and Company.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Dermatology | Heart | Inflammatory Bowel Disease | Nonmelanoma Skin Cancer | Psoriasis | Skin | Skin Cancer | Study | Ulcerative Colitis